ETOH - early phase senter
To accelerate the evaluation of innovative therapeutic approaches but also to ensure the level of care and quality of the process imposed by this type of trial, the IPC has created ETOH (Evaluation of Therapeutic Onco-Hematology), a unit dedicated exclusively to early clinical trials.
Approved and labeled by the ARS and granted by INCa in 2010, ETOH is the platform of PACA region for evaluating new drugs (in solid tumors and hematology).
Installed on 250 sqm on the 5th floor of the main building (IPC1), the ETOH unit is run by a highly specialized team of 16 people. It has 9 single rooms (5 beds are available on an outpatient basis), a treatment room, monitoring tools and a specific area allowing immediate treatment of blood and urine samples.
In addition to medical expertise of the Institute (surgery, radiotherapy, transplant ...), the team relies on the Therapeutic Intensive Care Unit (specializing in the care of patients with hematologic malignancies) and common technology platforms of the IPC and CRCM: scientific imaging, integrated biology, immunomonitoring, biobank ... administratively, the tests are monitored by the Department of Clinical Research and Innovation (DRCI).
To date ETOH has already led studies of 44 patients (19 in 2010 and 22 in 2011) among which the first administration in man of two drug candidates.
Date of creation: 2010
Staff (IPC and others): 4 MDs (including the 2 directors), 9 collaborating physicians (oncologists, hematologists and 1 radiologist), 1 research nurse, 1 clinical research assistant, 1 technician
Dr. Florence Broussais
Dr. Serge Brunelle
Dr. Gwenaëlle Gravis
Dr. Thomas Prébet